摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,7-二乙基-9-(4-(N-2-氨基乙基甲酰氨基甲氧基))苯基黄嘌呤 | 96865-92-8

中文名称
3,7-二乙基-9-(4-(N-2-氨基乙基甲酰氨基甲氧基))苯基黄嘌呤
中文别名
——
英文名称
xanthine amine congener
英文别名
N-(2-aminoethyl)-2-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)phenoxy]acetamide
3,7-二乙基-9-(4-(N-2-氨基乙基甲酰氨基甲氧基))苯基黄嘌呤化学式
CAS
96865-92-8
化学式
C21H28N6O4
mdl
——
分子量
428.491
InChiKey
FIQGIOAELHTLHM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    二甲基亚砜:>5mg/mL

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    31
  • 可旋转键数:
    10
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    134
  • 氢给体数:
    3
  • 氢受体数:
    6

安全信息

  • WGK Germany:
    3

SDS

SDS:ceb885d7108f55882aaf3a8ea54963d1
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    3,7-二乙基-9-(4-(N-2-氨基乙基甲酰氨基甲氧基))苯基黄嘌呤 在 palladium on activated charcoal 氢气1-羟基苯并三唑苯硫酚盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 0.25h, 生成 <α-aspartyl<8-<4-<<<<(aminoethyl)amino>carbonyl>methyl>oxy>phenyl>-1,3-dipropylxanthin-4.2-yl>>-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl-L-methionine amide trifluoroacetate
    参考文献:
    名称:
    Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors
    摘要:
    A "functionalized congener" approach to adenosine receptor antagonists has provided a means to synthesize highly potent peptide conjugates of 1,3-dialkylxanthines. The antagonist XAC, such a functionalized xanthine amine congener, has been attached to a segment derived from the neurotransmitter peptide substance P (SP) to form a binary drug that binds to both receptors with Ki values of 35 nM (central A1-adenosine) and 300 nM (striatal SP). Coupling of the functionalized adenosine agonist N6-[p-(carboxymethyl)phenyl]adenosine to an SP C-terminal peptide also resulted in a binary drug that binds to both receptors. The demonstration that the biochemical properties of two unrelated drugs, both of which act through binding at extracellular receptors, may be combined in the same molecule suggests a novel strategy for drug design. In principle, a combined effect of the two different substances that produce the same final effect (e.g., hypotension by adenosine agonists and by SP analogues) might occur in vivo. Adenosine analogues have analgesic properties, and the binary drug derived from substance P and adenosine agonists or antagonists might provide useful tools for probing interrelationships of SP pathways and sites for the antinociceptive action of adenosine.
    DOI:
    10.1021/jm00391a046
  • 作为产物:
    参考文献:
    名称:
    Xanthine functionalized congeners as potent ligands at A2-adenosine receptors
    摘要:
    Amide derivatives of a carboxylic acid congener of 1,3-dialkylxanthine, having a 4-[(carboxymethyl)oxy]phenyl substituent at the 8-position, have been synthesized in order to identify potent antagonists at A2-adenosine receptors stimulatory to adenylate cyclase in platelets. Distal structural features of amide-linked chains and the size of the 1,3-dialkyl groups have been varied. 1,3-Diethyl groups, more than 1,3-dimethyl or 1,3-dipropyl groups, favor A2 potency, even in the presence of extended chains attached at the 8-(p-substituted-phenyl) position. Polar groups, such as amines, on the chain simultaneously enhance water solubility and A2 potency. Among the most potent A2 ligands are an amine congener, 8-[4-[[[[(2-aminoethyl)amino]carbonyl]methyl]oxy]phenyl]- 1,3-diethylxanthine, and its D-lysyl conjugate, which have KB values of 21 and 23 nM, respectively, for the antagonism of N-ethyl-adenosine-5'-uronamide-stimulated adenylate cyclase activity in human platelet membranes. Strategies for the selection and tritiation of new radioligands for use in competitive binding assays at A2-adenosine receptors have been considered.
    DOI:
    10.1021/jm00384a037
点击查看最新优质反应信息

文献信息

  • Immunosuppressive effects of 8-substituted xanthine derivatives
    申请人:K.U. Leuven Research & Development
    公开号:US07253176B1
    公开(公告)日:2007-08-07
    The invention relates to a novel use of 8-substituted xanthine derivatives for the manufacture of a medicament for the treatment of auto-immuno disorders.
    这项发明涉及使用8-取代黄嘌呤衍生物制造治疗自身免疫性疾病药物的新方法。
  • Functionalized congeners of 1,3-dialkylxanthines: preparation of analogs with high affinity for adenosine receptors
    作者:Kenneth A. Jacobson、Kenneth L. Kirk、William L. Padgett、John W. Daly
    DOI:10.1021/jm00147a038
    日期:1985.9
    receptor antagonists. On the basis of the high potency of 8-(p-hydroxyphenyl)-1,3-dialkylxanthines, the parent compounds were 8-[4-[(carboxymethyl)oxy]phenyl] derivatives of theophylline and 1,3-dipropylxanthine. A series of analogues including esters of ethanol and N-hydroxysuccinimide, amides, a hydrazide, an acylurea, and anilides were prepared. The potency in blocking A1-adenosine receptors (inhibition
    一系列功能化的 1,3-二烷基黄嘌呤同源物已被制备作为腺苷受体拮抗剂。基于8-(对羟基苯基)-1,3-二烷基黄嘌呤的高效力,母体化合物是茶碱和1,3-二丙基黄嘌呤的8-[4-[(羧甲基)氧基]苯基]衍生物。制备了一系列类似物,包括乙醇和N-羟基琥珀酰亚胺的酯、酰胺、酰肼、酰基脲和苯胺。阻断 A1-腺苷受体(抑制 N6-[3H]环己基腺苷与脑膜的结合)和 A2-腺苷受体(抑制 2-氯腺苷引起的脑切片中环 AMP 积累)的效力受到结构变化的显着影响位于主要药效基团(8-苯基-1,3-二烷基黄嘌呤)的远端。二丙基系列对 A1 受体的效力范围从具有末端酰胺基乙烯胺部分的同源物的 Ki 值 1.2 nM,到母体羧酸的 Ki 值 58 nM,再到庞大的脲基同源物的 Ki 值 96 nM。某些同系物对 A1 受体的活性比对 A2 受体的活性高 145 倍。同系物的各种衍生物应可用作受体探针并用于放射性碘标记、抗生物素蛋白结合和亲和柱的制备。
  • Structure-Activity Relationships of 1,3-Dialkylxanthine Derivatives at Rat A3 Adenosine Receptors
    作者:Hea Ok Kim、Xiao-duo Ji、Neli Melman、Mark E. Olah、Gary L. Stiles、Kenneth A. Jacobson
    DOI:10.1021/jm00046a022
    日期:1994.9
    respectively. A synthetic strategy for introducing multiple carboxylate groups at the 8-position using iminodiacetic acid derivatives was explored. The presence of a sulfonate, a carboxylate, or multiple carboxylate groups did not result in a significant enhancement of affinity at rat A3 receptors, although as previously observed an anionic group tended to diminish potency at A1 and A2a receptors. The rat
    合成了在 8 位取代基上含有羧酸和其他带电基团的 1,3-二烷基黄嘌呤类似物。使用新的放射性配体 [125I]AB-MECA (N6-(4-amino-3-iodobenzyl)adenosine-5'-N-甲基糖醛酰胺),并分别使用 [3H]PIA 和 [3H]CGS 21680 作用于大鼠脑 A1 和 A2a 受体。探索了使用亚氨基二乙酸衍生物在 8 位引入多个羧酸酯基团的合成策略。磺酸盐、羧酸盐或多个羧酸盐基团的存在不会导致对大鼠 A3 受体的亲和力显着增强,尽管如前所述,阴离子基团倾向于降低对 A1 和 A2a 受体的效力。大鼠 A3 受体亲和力不高度依赖于羧酸盐基团与黄嘌呤药效团的距离。2-Thio 与 2-oxo 取代有利于 A3 效力,8-烷基与 8-芳基取代有利于 A3 选择性,尽管很少有衍生物对大鼠 A3 受体具有真正的选择性。1,3-Dimethyl-8-(3-carb
  • [EN] METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF<br/>[FR] DÉRIVÉS DE MÉTHANOCARBA-ADÉNOSINE ET CONJUGUÉS DE DENDRIMÈRE DE CEUX-CI
    申请人:US HEALTH
    公开号:WO2011068978A1
    公开(公告)日:2011-06-09
    Disclosed are (N)-methanocarba adenine nucleosides, e.g., of the formula (I): as A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein A, a, R2, and R3 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. Also disclosed are conjugates comprising a dendrimer and one or more ligands, which are functionalized congeners of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily. Such conjugates are have the potential of being used as dual agonists, dual antagonists, or agonist/antagonist combinations.
    揭示了(N)-methanocarba腺嘌呤核苷,例如,化学式(I)所示的腺苷受体A3激动剂,包括这种核苷的药物组合物,以及这些核苷的使用方法,其中A、a、R2和R3如规范中定义。这些核苷被考虑用于治疗多种疾病,例如炎症、心脏缺血、中风、哮喘、糖尿病和心律失常。还揭示了包括树枝状聚合物和一个或多个配体的共轭物,这些配体是G蛋白偶联受体(GPCR)超家族受体的激动剂或拮抗剂的功能化同系物。这种共轭物有潜力用作双激动剂、双拮抗剂或激动剂/拮抗剂组合物。
  • 2-Aminopyridine compounds and use thereof as drugs
    申请人:——
    公开号:US20040006082A1
    公开(公告)日:2004-01-08
    The present invention provides 2-aminopyridine compound having an excellent adenosine receptor (A 1 , A 2a , A 2b receptors) antagonism, which is represented by the following formula: 1 (wherein, R 1 represents cyano group, carboxyl group or an optionally substituted carbamoyl group; R 2 represents hydrogen atom, hydroxyl group, an optionally substituted C 1-6 alkoxy group, an optionally substituted C 6-14 aromatic hydrocarbon cyclic group or an optionally substituted 5- to 14-membered aromatic heterocyclic group; and R 3 and R 4 are the same as or different from each other and each represents a C 6-14 aromatic hydrocarbon cyclic group, a 5- to 14-membered non-aromatic heterocyclic group or a 5- to 14-membered aromatic heterocyclic group which may be substituted, respectively) or a salt thereof.
    本发明提供了一种具有优异腺苷受体(A1、A2a、A2b 受体)拮抗作用的 2-氨基吡啶化合物,其化学式如下:1(其中,R1代表氰基、羧基或可选择取代的氨基甲酰基;R2代表氢原子、羟基、可选择取代的C1-6烷氧基、可选择取代的C6-14芳香烃环基或可选择取代的 5-到 14-成员芳香杂环基;R3和 R4相同或不同,分别代表 C6-14芳香烃环基、 5-到 14-成员非芳香杂环基或可选择取代的 5-到 14-成员芳香杂环基,或其盐。
查看更多